Fig. 5
RhoA-ROCK positively regulates the canonical Wnt/β-catenin signaling pathway of WPMY-1 and BPH-1 cells. A Immunoblot assay of proteins in relation to canonical Wnt/β-catenin signaling pathway (Wnt1, GSK-3β, p-GSK-3β, β-catenin, C-MYC, Survivin, Snail and CyclinD1) in WPMY-1 and BPH-1 cells after RhoA knockdown. B Immunoblot assay of proteins in relation to canonical Wnt/β-catenin signaling pathway in WPMY-1 and BPH-1 cells after RhoA overexpression. C Immunofluorescence staining of RhoA and β-catenin for WPMY-1 and BPH-1 cells after RhoA knockdown. DAPI (blue) indicates nuclear staining, FITC-immunofluorescence (green) indicates β-catenin protein staining, and Cy3-immunofluorescence (red) indicates RhoA protein staining. D The stability of β-catenin protein determined by immunoblot assay in WPMY-1 and BPH-1 cells after RhoA knockdown. E The expression of β-catenin protein after proteasome inhibition determined by immunoblot assay in WPMY-1 and BPH-1 cells. F Immunoblot assay of β-catenin in WPMY-1 and BPH-1 cells after different concentrations of Y-27632 treatment for 48 h. G GTEx analysis of the correlation between CTNNB1 and RhoA, ROCK1 and ROCK2 in prostate. Data were expressed as mean ± SD. ns means no significant difference, * p < 0.05, **p < 0.01, ***p < 0.001